Transderm-V en es it fr

Transderm-V Brand names, Transderm-V Analogs

Transderm-V Brand Names Mixture

  • No information avaliable

Transderm-V Chemical_Formula


Transderm-V RX_link

No information avaliable

Transderm-V fda sheet

Transderm-V msds (material safety sheet)

Transderm-V Synthesis Reference

No information avaliable

Transderm-V Molecular Weight

303.353 g/mol

Transderm-V Melting Point

No information avaliable

Transderm-V H2O Solubility

No information avaliable

Transderm-V State


Transderm-V LogP


Transderm-V Dosage Forms


Transderm-V Indication

For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.

Transderm-V Pharmacology

Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.

Transderm-V Absorption

No information avaliable

Transderm-V side effects and Toxicity

No information avaliable

Transderm-V Patient Information

No information avaliable

Transderm-V Organisms Affected

Humans and other mammals